Comparative Risk of Herpes Zoster and Pneumonia Among Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis: A Propensity Score-Matched Analysis of the TriNetX Research Network (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1404; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "In this propensity score-matched real-world analysis, HZ risk was low and similar across TOFA, BARI, and UPA. HZ incidence was lower than previously reported in JAKi-treated populations, possibly reflecting vaccination effects, coding limitations, or exclusion of patients with prior HZ. Pneumonia risk was higher with BARI than TOFA and UPA, most consistently at 2 years."
Asthma • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Varicella Zoster
|
|
Asmaa Beltagy1; Varote Shotelersuk2; Miriam Paz Sierra3; Nattanicha Chaisrimaneepan4; Nouran Eshak5
|